Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chad Hodge

Nurse Practitioner Lake Charles, LA Nurse Practitioner

NPI 1154854255 CMS profile 10520491

501 Doctor Michael Debakey Dr, Lake Charles, LA 70601

Open in the dashboard

General payments

$10,815

583 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chad Hodge of Lake Charles, LA is reported in the CMS Open Payments database as having received $10,815 across 583 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,400 124
2024 General $2,134 106
2023 General $2,463 130
2022 General $2,249 126
2021 General $1,570 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chad Hodge
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Chad Hodge were reported at $2,400. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Chad Hodge Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,570 $135 $40–$426 $132
2022 $2,249 $152 $48–$470 $149
2023 $2,463 $166 $54–$529 $160
2024 $2,134 $173 $55–$556 $164
2025 $2,400 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $3,225 204 payments
  2. AstraZeneca Pharmaceuticals LP $2,351 138 payments
  3. Genzyme Corporation $1,198 51 payments
  4. Regeneron Healthcare Solutions, Inc. $897 36 payments
  5. CSL Behring $797 35 payments
  6. Baxter Healthcare $339 15 payments
  7. Mylan Specialty L.P. $296 12 payments
  8. Insmed, Inc. $287 13 payments
  9. Viatris Specialty LLC $271 16 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $233 14 payments
  11. Other $920 49 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,683 580 payments
  2. Education $133 3 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,846 100 payments
  2. NUCALA $1,754 123 payments
  3. DUPIXENT Immunology $1,198 51 payments
  4. BREZTRI $1,013 62 payments
  5. AREXVY $803 40 payments
  6. FASENRA $801 45 payments
  7. Hizentra $797 35 payments
  8. DUPIXENT Inflammation And Immunology $623 25 payments
  9. YUPELRI $566 28 payments
  10. TEZSPIRE $313 18 payments
  11. Other $2,761 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$14,073

Medicare's payments for the services billed

Medicare patients

48

Average age 74

Services billed

258

16 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
COPD 75%
Atrial fibrillation 69%
Chronic kidney disease 69%
Ischemic heart disease 65%
Diabetes 63%
Depression 56%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $243
  • Regeneron Healthcare Solutions, Inc. $200
$443 — —
AREXVY
  • GlaxoSmithKline, LLC. $250
$250 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $221
$221 — —
NUCALA
  • GlaxoSmithKline, LLC. $213
$213 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $123
  • Amgen Inc. $72
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

583 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record